Cardiac Rhythm Management Devices – Market Insights – Japan

The Japanese CRM device market will grow over the forecast period. The introduction of novel products—such as the Aurora EV-ICD and dual-chamber leadless pacemakers—and favorable reimbursement will drive overall pulse generator unit volume growth in Japan. However, the market will be limited to some extent by MHLW reimbursement cuts.

This Medtech 360 Report provides comprehensive data and analysis on the state of the Japanese cardiac rhythm management device market from 2019 through 2034.

Adoption of novel devices will drive growth in the Japanese CRM device market.

How will recent approvals of dual-chamber leadless pacemakers and extravascular ICDs affect overall market growth?

How will these devices impact trends for other types of devices?

Clinical trials continue to play a critical role in the CRM device market.

What are the major ongoing trials that will potentially impact the CRM device market?

What are the results from these trials?

How will clinical data drive the demand for device segments with advanced data-sharing capabilities to enhance patient outcomes?

The CRM device market will be supported by competitors’ product innovations.

How does new technology influence growth across different pulse generator product segments?

Which segments are expected to see dynamic growth, and which segments will decline due to product cannibalization?

How can individual competitors realize growth in this large and growing market?

The MHLW‘s biennial reimbursement revisions are having a significant impact on pricing trends.

How do the MHLW‘s biennial reimbursement revisions differ across device segments? How will the 2024 revisions impact market growth?

How do ASP trends for novel devices differ from those for more established devices? What changes have been made to the reimbursement of novel devices?